Overview

Ipilimumab and Nivolumab in Leptomeningeal Metastases

Status:
Active, not recruiting
Trial end date:
2021-09-01
Target enrollment:
Participant gender:
Summary
This research study is studying a combination of two drugs as a possible treatment for Leptomeningeal Metastases. The names of the study interventions involved in this study are: - Ipilimumab - Nivolumab
Phase:
Phase 2
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborator:
Bristol-Myers Squibb
Treatments:
Antibodies, Monoclonal
Ipilimumab
Nivolumab